Phase 1CompletedINTERVENTIONAL
Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov · NCT03059719 · Registry updated: 2017-02-23
- Condition / research focus
- Type II Diabetes Mellitus
- Sponsor
- PegBio Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2015-04-08. Completion: 2016-10-27 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Exenatide injection(Byetta) (biological)
- PB-119 injection (biological)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- No.1 Hospital of Peking University
Beijing, Beijing Municipality, China
Site recruitment: Not reported